Stock News

NewLink Genetics (NLNK) Reaches $4.12 Yearly Low; ALFA-LAVAL AB ORDINARY SHARES SWEDEN (ALFVF) Shorts Increased By 4.18%

NewLink Genetics Corporation (NASDAQ:NLNK) Logo

The stock of NewLink Genetics Corporation (NASDAQ:NLNK) hit a new 52-week low and has $3.91 target or 5.00% below today’s $4.12 share price. The 7 months bearish chart indicates high risk for the $152.90 million company. The 1-year low was reported on Apr, 16 by Barchart.com. If the $3.91 price target is reached, the company will be worth $7.64M less. The stock decreased 7.94% or $0.355 during the last trading session, reaching $4.115. About 1.62M shares traded or 46.10% up from the average. NewLink Genetics Corporation (NASDAQ:NLNK) has declined 65.28% since April 16, 2017 and is downtrending. It has underperformed by 76.83% the S&P500.

ALFA-LAVAL AB ORDINARY SHARES SWEDEN (OTCMKTS:ALFVF) had an increase of 4.18% in short interest. ALFVF’s SI was 580,300 shares in April as released by FINRA. Its up 4.18% from 557,000 shares previously. The SI to ALFA-LAVAL AB ORDINARY SHARES SWEDEN’s float is 0.2%. It closed at $23.54 lastly. It is down 0.00% since April 16, 2017 and is . It has underperformed by 11.55% the S&P500.

NewLink Genetics Corporation, a biopharmaceutical company, focuses on discovering, developing, and commercializing immunotherapeutic products for the treatment of cancer. The company has market cap of $152.90 million. The Company’s portfolio includes biologic product candidates based on its HyperAcute cellular immunotherapy technology, which is designed to stimulate the human immune system to attack cancer cells; and small-molecule product candidates that are focused on breaking the immune system's tolerance to cancer by inhibiting the indoleamine-2, 3-dioxygenase pathway and the tryptophan-2, 3-dioxygenase pathway. It currently has negative earnings. The firm is developing IDO pathway inhibitors comprising indoximod that is in multiple Phase I and Phase II clinical trials for patients with melanoma, pancreatic cancer, malignant brain tumors, metastatic breast cancer, acute myeloid leukemia, prostate cancer, and non-small cell lung cancer ; and GDC-0919 and atezolizumab (MPDL3280A) that is in Phase Ib clinical trials for patients with locally advanced or metastatic solid tumors.

Among 6 analysts covering NewLink Genetics (NASDAQ:NLNK), 1 have Buy rating, 0 Sell and 5 Hold. Therefore 17% are positive. NewLink Genetics has $3200 highest and $400 lowest target. $8.83’s average target is 114.58% above currents $4.115 stock price. NewLink Genetics had 21 analyst reports since March 23, 2016 according to SRatingsIntel. SunTrust downgraded the shares of NLNK in report on Monday, April 9 to “Hold” rating. As per Friday, April 6, the company rating was downgraded by Jefferies. The firm has “Buy” rating by Robert W. Baird given on Friday, October 13. The firm has “Neutral” rating by Robert W. Baird given on Monday, April 9. Cantor Fitzgerald downgraded NewLink Genetics Corporation (NASDAQ:NLNK) on Monday, April 9 to “Neutral” rating. The company was maintained on Friday, March 2 by Bank of America. Stifel Nicolaus maintained the stock with “Buy” rating in Thursday, August 31 report. The company was upgraded on Friday, September 8 by Jefferies. The firm has “Hold” rating by Jefferies given on Thursday, June 8. Robert W. Baird initiated NewLink Genetics Corporation (NASDAQ:NLNK) on Wednesday, March 23 with “Outperform” rating.

Investors sentiment increased to 1.51 in Q4 2017. Its up 0.29, from 1.22 in 2017Q3. It improved, as 22 investors sold NewLink Genetics Corporation shares while 21 reduced holdings. 28 funds opened positions while 37 raised stakes. 23.56 million shares or 27.79% more from 18.44 million shares in 2017Q3 were reported. 1,170 are owned by North Star Invest. American Grp Incorporated stated it has 19,558 shares or 0% of all its holdings. California Pub Employees Retirement Systems reported 0% of its portfolio in NewLink Genetics Corporation (NASDAQ:NLNK). Stifel Corporation holds 0% of its portfolio in NewLink Genetics Corporation (NASDAQ:NLNK) for 21,900 shares. Zacks Mngmt owns 0% invested in NewLink Genetics Corporation (NASDAQ:NLNK) for 15,694 shares. Bridgeway Cap Management Incorporated has invested 0.01% of its portfolio in NewLink Genetics Corporation (NASDAQ:NLNK). State Common Retirement Fund invested in 21,800 shares. Deutsche National Bank & Trust Ag has 0% invested in NewLink Genetics Corporation (NASDAQ:NLNK) for 172,503 shares. Voya Investment Management Limited Liability Com owns 12,626 shares. Raymond James & Associates accumulated 0% or 29,576 shares. Parallax Volatility Advisers Limited Partnership holds 0% of its portfolio in NewLink Genetics Corporation (NASDAQ:NLNK) for 4,452 shares. Invesco Ltd, Georgia-based fund reported 14,355 shares. Commercial Bank Of New York Mellon accumulated 117,179 shares. Acadian Asset Mngmt holds 19,470 shares or 0% of its portfolio. Connor Clark & Lunn Management reported 452,160 shares.

Analysts await NewLink Genetics Corporation (NASDAQ:NLNK) to report earnings on May, 3. They expect $-0.55 EPS, up 23.61% or $0.17 from last year’s $-0.72 per share. After $-0.37 actual EPS reported by NewLink Genetics Corporation for the previous quarter, Wall Street now forecasts 48.65% negative EPS growth.

NewLink Genetics Corporation (NASDAQ:NLNK) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *